Pacific Biosciences of California, Inc.
PACB
$1.13
$0.043.67%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -32.79% | -28.23% | -24.30% | -0.23% | 113.35% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -32.79% | -28.23% | -24.30% | -0.23% | 113.35% |
| Cost of Revenue | -28.63% | -28.83% | -31.39% | -9.57% | 147.07% |
| Gross Profit | -45.44% | -26.99% | -9.95% | 26.96% | 50.76% |
| SG&A Expenses | 21.84% | -15.16% | -5.41% | 9.88% | 2.21% |
| Depreciation & Amortization | 0.01% | 640.54% | 3,643.17% | 3,642.62% | 834.38% |
| Other Operating Expenses | -70.95% | -- | -- | -- | -- |
| Total Operating Expenses | -11.15% | -25.87% | -16.09% | 1.99% | 36.38% |
| Operating Income | -3.46% | 24.09% | 10.61% | -3.08% | -9.65% |
| Income Before Tax | 103.25% | 21.72% | -148.19% | 11.18% | 1.95% |
| Income Tax Expenses | 144.01% | -- | -- | -- | -- |
| Earnings from Continuing Operations | 102.89% | 9.19% | -148.19% | 11.18% | 2.80% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 102.89% | 9.19% | -148.19% | 11.18% | 2.80% |
| EBIT | -3.46% | 24.09% | 10.61% | -3.08% | -9.65% |
| EBITDA | -4.08% | 35.71% | 21.78% | 6.14% | -0.72% |
| EPS Basic | 102.74% | 15.14% | -127.82% | 20.26% | 17.69% |
| Normalized Basic EPS | -0.15% | 28.55% | 13.37% | 5.17% | 11.92% |
| EPS Diluted | 102.65% | 15.14% | -128.57% | 20.26% | 16.97% |
| Normalized Diluted EPS | 7.65% | 28.55% | 13.37% | 5.17% | 11.92% |
| Average Basic Shares Outstanding | 5.94% | 7.03% | 8.92% | 11.38% | 18.07% |
| Average Diluted Shares Outstanding | 14.89% | 7.03% | 8.92% | 11.38% | 18.07% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |